33607 - CXCL9 (plasma)
Cytokines and chemokines play critical roles in regulating innate and adaptive immune responses. Quantitative assessment of immune signaling biomarkers can provide insight into inflammatory pathways associated with immune activation.
About Test
CXCL9 (also known as Monokine Induced by Gamma Interferon [MIG]) is an IFN-γ-inducible chemokine that plays a central role in T cell-mediated immune activation and trafficking. It signals through the CXCR3 receptor, recruiting activated T cells to sites of inflammation and allograft injury. Quantitative measurement of CXCL9 in plasma provides a non-invasive assessment of ongoing immune activation that may precede clinical signs of rejection or immune dysregulation.
ProcedureQuantitative Multiplex Fluorescence Immunoassay. This test was developed and its performance characteristics were determined by Eurofins Viracor. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specificity<2% off-target recovery when tested using samples individually spiked with 1400, 900, & 500 pg/mL CXCL10 or 3000, 2000, & 1200 pg/mL IL-18
24 hours from receipt of specimen. To meet the 24-hour turnaround time, test orders will need to be received at the lab by 11am CST. Monday - Saturday.
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| plasma | 33607 | 83520 | No | 1 mL (min. 200 uL) |
77-18704 pg/mL |
|
The reference range for a healthy population is less than 77 pg/mL. The reference range for this assay was determined from a population of healthy adults
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Eurofins Viracor’s interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References- Goutaudier V, et al. Detection of Kidney Allograft Rejection Using Urinary Chemokines. J Am Soc Nephrol. 2025;36(11):2228-2240. https://doi.org/10.1681/ASN.0000000742
- Macinioniene E, et al. Urinary Chemokines CXCL9 and CXCL10. Ann Transplant. 2024;29:e944762. https://doi.org/10.12659/AOT.944762
- Tinel C, et al. Sci Rep. 2024;14(1):20357. https://doi.org/10.1038/s41598-024-70390-x
- Shino MY, et al. Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. Am J Transplant. 2022;22(9):2169-2179. https://doi.org/10.1111/ajt.17108
- Ciftci HS, et al. Int J Organ Transplant Med. 2019;10(2):53-63. PMC6604756
- Kim SC, et al. Transplant Rev. 2014;28(1):15-20. https://doi.org/10.1016/j.trre.2013.10.004
- Moy RH, et al. Blood. 2017;129(7):906-916. https://doi.org/10.1182/blood-2016-08-735076